192564-14-0

Hazard Information

Questions And Answer

• Clinical Effects

  Oritavancin diphosphate will most probably be prescribed as a once-daily dose and it demonstrates concentration-dependent bactericidal activity. Various clinical studies of oritavancin diphosphate have shown good performance. Oritavancin diphosphate has demonstrated preliminary safety and efficacy in Phase I and II clinical trials. In a Phase III clinical trial, oritavancin diphosphate has achieved the primary efficacy end point in the treatment of complicated Gram-positive skin and skin-structure infections. To date, adverse events have been mild and limited; the most common being administration site complaints, headache, rhinitis, dry skin, pain, increases in liver transaminases and accumulation of free cholesterol and phospholipids in phagocytic (macrophages) and nonphagocytic (fibroblast) cells.

  ;

Supplier

Related Products